[1] Burch HB,Wartofsky L.Graves ophthalmopathy:current con-cepts regarding pathogenesis and management[J]. Endocr Rev,1993,14(6):747-793. [2] Jacobson D,Gorman CA.Endocrine ophthalmopathy:current ide-as conceming etiology,pathogenesis,and treatment[J]. Endocr Rev,1984,5(2):200-220. [3] 乔翠芳.甲状腺相关眼病球后、半球后注射曲安奈德的治疗[J]. 包头医学,2007,31(4):201. [4] Bartalena L,Pinchera A,Marcocci C.Management of Graves ophthalmopathy:reality and perspectives[J]. Endocr Rev,2000,21(2):168-199. [5] Luigi Bartalena MD,Maria Laura Tanda MD.Graves ophthalmop-athy[J]. N Engl J Med,2009,360:994-1001. [6] Alfonso EC,Forster RK,Garg P,et al.Fungal infections.In:Fos-ter CS,Azar DT,Dohlman CH,eds.Smolin and Thofts The Cor-nea Scientific Foundations & Clinical Practice[M]. 4th ed.Bal-timore,MD:Lippincott Williams & Wilkins,2005:405-416. [7] Harissi-Dagher M,Colby K.Fungal infections of the cornea[J]. Contemp Ophthalmol,2006,5:1-8. [8] Jurkunas U,Behlau 1,Colby K,et al.Fungal keratitis:changing pathogens and risk factors[J]. Comen,2009,28(6):638-643. [9] Loh AR,Hong K,Lee S,et al.Practice patterns in the manage-ment of fungal corneal ulcers[J]. Cornea,2009,28 (8):856-859. [10] Ou JI,Acharya NR.Epidemiology and treatment of fungal come-al ulcers[J]. Int Ophthahnol Clin,2007,47(3):7-16. [11] O Day DM.Selection of appropriate antifungal therapy[J]. Cor-nea,1987,6(4):238-245. [12] Bartalena L,Baldeschi L,Dickinson A,et al.Consensus state-ment of the European group on Graves orbitopathy (EUGOGO) on management of GO[J]. Eur J Endocrinol,2008,158(3):273-285. [13] Idem.Consensus statement of the European group on Graves or-bitopathy (EUGOGO) on management of Graves orbitopathy[J]. Thyroid,2008,18(3):333-346. |